AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
KORU Medical Systems, Inc.
Video analysis: KRMD
All videosNo video analysis for this stock yet. Request one from our team.
News: KRMD
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
KORU Medical Systems Q2 Earnings Call Highlights
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates
KORU Medical Systems, Inc. (KRMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical's management is scheduled to present at the Canaccord Genuity 46th Annual.
Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company's current shareholders.The investigation seeks to determine whether KORU and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.KORU shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information abo.
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.
